Radius Health to Announce First Quarter 2016 Financial Results, Host Conference Call and Live Webcast on May 5, 2016

WALTHAM, Mass., April 12, 2016 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its first quarter 2016 financial results on Thursday, May 5, 2016.

In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 8:00 a.m. ET on Thursday, May 5, 2016 to discuss the results and provide a company update.

Conference Call Information:

Date: Thursday, May 5, 2016

Time: 8:00 a.m. ET

Domestic Dial-in Number: 1-877-705-6003

International Dial-in Number: 1-201-493-6725

Live webcast: http://public.viavid.com/index.php?id=119098

For those unable to participate in the conference call or webcast, a replay will be available beginning May 5, 2016 at 10:30 a.m. ET until May 19, 2016 at 11:59 p.m. ET. To access the replay, dial 1-877-870-5176 or 1-858-384-5517. The replay pin number is 13635038.

A live audio webcast of the call will also be available on the Investors section of the Company's website, www.radiuspharm.com. A webcast replay will be available for 14 days on the Radius website, www.radiuspharm.com. The full text of the announcement and financial results will also be available on the Company's website.

About Radius
Radius is a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis. Radius’ Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe and a New Drug Application (NDA) was submitted in the U.S. at the end of the first quarter of 2016. The Radius clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius' preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in multiple applications including cancer.

CONTACT: Investor Relations Barbara Ryan 203-274-2825 bryan@radiuspharm.com Media Lori Gorski 617-551-4096 lgorski@radiuspharm.com

Source:Radius Health Inc.